Ablating Satb1 reprograms the differentiation trajectory of exhausted CD8+ T subsets to enhance antitumor immunity - Top-Institutions - MDSpire

Ablating Satb1 reprograms the differentiation trajectory of exhausted CD8+ T subsets to enhance antitumor immunity

  • By

  • Linwei Wu

  • Haolin Jiang

  • Jianling Gao

  • Xiaolan Ji

  • Yu Chen

  • Zhenghao Ma

  • Xinying Li

  • Jin Wang

  • Yachen Zang

  • Ji Zhang

  • Xin Zhao

  • Xuefeng Wang

  • June 22, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Northwestern University Feinberg School of Medicine / Robert H. Lurie Comprehensive Cancer Center
    Northwestern University Feinberg School of Medicine / Robert H. Lurie Comprehensive Cancer Center

    Chicago, Illinois

    Key Differentiators

    • Immunology
    • Oncology

  • #2

    University of Pennsylvania (Penn Medicine) / Abramson Cancer Center
    University of Pennsylvania (Penn Medicine) / Abramson Cancer Center

    Philadelphia, Pennsylvania

    Key Differentiators

    • Immunology
    • Oncology

  • #3

    Fred Hutchinson Cancer Research Center
    Fred Hutchinson Cancer Research Center

    Seattle, Washington

    Key Differentiators

    • Immunology
    • Oncology

  • #4

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Immunology
    • Oncology

  • #5

    Hiroshima University
    Hiroshima University

    Hiroshima, Japan

    Key Differentiators

    • Immunology
    • Oncology

Original Source(s)

Ablating Satb1 reprograms the differentiation trajectory of exhausted CD8+ T subsets to enhance antitumor immunity

  • by Linwei Wu, Haolin Jiang, Jianling Gao, Xiaolan Ji, Yu Chen, Zhenghao Ma, Xinying Li, Jin Wang, Yachen Zang, Ji Zhang, Xin Zhao, Xuefeng Wang

  • June 22, 2026

Related Content

Association between radiotherapy timing and intracranial outcomes in EGFR-mutant NSCLC with brain metastases treated with EGFR-TKIs

Editorial: The role of immune and stromal mediators in the formation of pre-metastatic and metastatic niches: the gateway to metastasis

Antibody-drug conjugates in colorectal cancer: current landscape and future perspectives from clinical trials